Semaglutide, with its single-agonist function, offers substantial efficacy, while Zepbounds dual-action on GLP-1 and GIP receptors might render it a more potent contender alongside vigilant monitoring for adverse effects
According to the PIONEER TEENS study topline results announced by the company, the drug reduced blood sugar by 0.83 per cent and showed a well-tolerated safety profile consistent with previous semaglutide trials
Novos main rival, Eli Lilly, the maker of the popular Mounjaro and Zepbound jabs, is not far behind, with the US launch of its weight-loss pill orforglipron expected as soon as April
adults are clinically obese, making obesity a major health concern linked to numerous chronic diseases and health issues
they may arise secondarily due to hypoglycemia (low blood sugar level), dehydration, gastrointestinal side effects, and interaction of semaglutide with other medications